Breo Launch Timing Slips But No “Drama,” GSK’s Witty Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The once-daily COPD medication Breo is an important launch for GSK, and the company has pushed back the timing by a few weeks, potentially into the fourth quarter, to make sure it is “nailed,” CEO Witty says during the company’s second quarter call. Nonetheless, Breo may be experiencing more pushback from payers than GSK expected.